# Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

> **NCT02638428** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 90 (estimated)

## Conditions studied

- Relapsed Pediatric Solid Tumor
- Refractory Pediatric Solid Tumor
- Relapsed Pediatric AML
- Refractory Pediatric AML

## Interventions

- **PROCEDURE:** CancerSCAN™
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Pazopanib
- **DRUG:** Sorafenib
- **DRUG:** Axitinib
- **DRUG:** Crizotinib
- **DRUG:** Dasatinib
- **DRUG:** Erlotinib
- **DRUG:** Everolimus
- **DRUG:** Imatinib
- **DRUG:** Ruxolitinib
- **DRUG:** Vandetanib
- **DRUG:** Vemurafenib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02638428
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2021-12
- **Final completion:** 2023-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02638428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02638428, "Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02638428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*